Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
NCT05177536
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is testing a medicine called iberdomide to see if it is safe and helps patients after they have a stem cell transplant to treat their blood disease. The medicine will be taken daily for 21 days, followed by a 7-day break. The study will have up to 38 patients. If the results are good, they may do a bigger study to compare iberdomide to another medicine called lenalidomide.
This study is testing a medicine called iberdomide to see if it is safe and helps patients after they have a stem cell transplant to treat their blood disease. The medicine will be taken daily for 21 days, followed by a 7-day break. The study will have up to 38 patients. If the results are good, they may do a bigger study to compare iberdomide to another medicine called lenalidomide.
Third Opinion AI Generated Synopsis
Trial Summary
This study will determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Treatment will continue until disease progression or toxicity. The results from this study will inform the feasibility of pursuing a study comparing iberdomide to lenalidomide maintenance post-ASCT.
This study will determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Treatment will continue until disease progression or toxicity. The results from this study will inform the feasibility of pursuing a study comparing iberdomide to lenalidomide maintenance post-ASCT.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
